Effects of Obesity on Rectus Femoris Muscle Thickness, Sarcopenia, Gait and Balance in Women

Obesity Clinical Trial

Official title:

Effects of Obesity on Rectus Femoris Muscle Thickness, Sarcopenia, Gait and Balance in Women

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05638035
• Other study ID #: DSA2022
• Status: Enrolling by invitation
• Start date: October 15, 2022
• Est. completion date: June 15, 2023

Study information

• Verified date: November 2022
• Source: Kutahya Health Sciences University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Research; It is a planned, non-invasive, controlled study in obese female volunteers and non-obese female volunteers. The population of the study consists of voluntarily non-obese women and obese women. Sarcopenia assets of individuals will be measured with the sarc-f questionnaire, and then muscle strength, muscle mass and physical performance tests will be measured. Then, rectus femoris muscle thickness will be measured with USG, and then walking and balance will be measured with ZEBRIS.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1
• Est. completion date: June 15, 2023
• Est. primary completion date: March 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Being over 18 years old and female

• Volunteering and accepting to participate in the study

• BMI 30-39.9 kg/m2 in obese women (experimental group)

• BMI 18-27.9 kg/m2 in non-obese women (control group)

• Not having cardiorespiratory, neurological, orthopedic and metabolic disorders

Exclusion Criteria:

• Being under 18 years old and male

• Having a BMI of 40.0 kg/m2 and above in obese women (experimental group)

• BMI 28.0 kg/m2 and above in non-obese women (control group)

• Having cardiorespiratory, neurological, orthopedic and metabolic disorders

Related Conditions & MeSH terms

• Obesity
• Sarcopenia
• Sarcopenic Obesity

Intervention

Diagnostic Test:
• Ultrasonografi, Sarcopenia measurement, Zebris
The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported. TANITA for sarcopenia, hand grip strength and walking speed will be evaluated. Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2.

Locations

Country	Name	City	State
Turkey	Kütahya Health Sciences University	Kütahya	Centre

Sponsors (1)

Lead Sponsor	Collaborator
Kutahya Health Sciences University

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Ates Bulut E, Soysal P, Dokuzlar O, Kocyigit SE, Aydin AE, Yavuz I, Isik AT. Validation of population-based cutoffs for low muscle mass and strength in a population of Turkish elderly adults. Aging Clin Exp Res. 2020 Sep;32(9):1749-1755. doi: 10.1007/s40520-019-01448-4. Epub 2020 Jan 2. — View Citation

Dutil M, Handrigan GA, Corbeil P, Cantin V, Simoneau M, Teasdale N, Hue O. The impact of obesity on balance control in community-dwelling older women. Age (Dordr). 2013 Jun;35(3):883-90. doi: 10.1007/s11357-012-9386-x. Epub 2012 Feb 10. — View Citation

Mueller N, Murthy S, Tainter CR, Lee J, Riddell K, Fintelmann FJ, Grabitz SD, Timm FP, Levi B, Kurth T, Eikermann M. Can Sarcopenia Quantified by Ultrasound of the Rectus Femoris Muscle Predict Adverse Outcome of Surgical Intensive Care Unit Patients as well as Frailty? A Prospective, Observational Cohort Study. Ann Surg. 2016 Dec;264(6):1116-1124. doi: 10.1097/SLA.0000000000001546. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rectus femoris muscle thickness	Measurement of muscle thickness with ultrasound	baseline